Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial.
Rodríguez PC, Prada DM, Moreno E, Aira LE, Molinero C, López AM, Gómez JA, Hernández IM, Martínez JP, Reyes Y, Milera JM, Hernández MV, Torres R, Avila Y, Barrese Y, Viada C, Montero E, Hernández P. Rodríguez PC, et al. Clin Exp Immunol. 2018 Feb;191(2):229-239. doi: 10.1111/cei.13061. Epub 2017 Nov 16. Clin Exp Immunol. 2018. PMID: 28963724 Free PMC article. Clinical Trial.
A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.
Rodriguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, Hernandez IM, Hernandez MV, Martinez JP, Hernandez X, Casaco A, Ramos M, Avila Y, Barrese Y, Montero E, Hernandez P. Rodriguez PC, et al. Results Immunol. 2012 Nov 21;2:204-11. doi: 10.1016/j.rinim.2012.11.001. eCollection 2012. Results Immunol. 2012. PMID: 24371585 Free PMC article.
CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
Crombet Ramos T, Rodríguez PC, Neninger Vinageras E, Garcia Verdecia B, Lage Davila A. Crombet Ramos T, et al. Among authors: rodriguez pc. Expert Rev Vaccines. 2015;14(10):1303-11. doi: 10.1586/14760584.2015.1079488. Epub 2015 Aug 20. Expert Rev Vaccines. 2015. PMID: 26295963 Review.
Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
Popa X, García B, Fuentes KP, Huerta V, Alvarez K, Viada CE, Neninger E, Rodríguez PC, González Z, González A, Crombet T, Mazorra Z. Popa X, et al. Among authors: rodriguez pc. Oncoimmunology. 2020 May 25;9(1):1762465. doi: 10.1080/2162402X.2020.1762465. Oncoimmunology. 2020. PMID: 32923124 Free PMC article.
Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.
Rodriguez PC, Neninger E, García B, Popa X, Viada C, Luaces P, González G, Lage A, Montero E, Crombet T. Rodriguez PC, et al. J Immune Based Ther Vaccines. 2011 Oct 24;9:7. doi: 10.1186/1476-8518-9-7. J Immune Based Ther Vaccines. 2011. PMID: 22024351 Free PMC article.
144 results